Targovax ASA, a clinical stage company focused on immuno-oncology therapies against solid tumors, on Monday revealed that three posters were presented during the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from September 8-12.
Oystein Soug, Chief Executive Officer of Targovax, said that the ESMO annual conference is a place where clinicians and researchers from all over the world gather to share important information with the goal of finding effective cancer treatments and that the company is delighted that ESMO allowed them to participate with three posters in the forum.
Soug said that the the data in the posters highlight some of the important progress the company has made to date in the clinic with its two novel proprietary immunotherapy technology platforms. The two posters summarizing the encouraging data from early clinical studies with TG01, from the neo-antigen therapeutic cancer vaccine platform, suggest it may have significant potential in the treatment of RAS-mutated pancreatic cancer, which currently has a poor prognosis, Soug said. THe CEO also said that the third poster relates to an ongoing phase I/II study in mesothelioma, a rare and difficult to treat cancer, with the lead drug candidate from our oncolytic virus platform, ONCOS-102.